Related Experiment Video
Updated: Dec 25, 2025

Single-Cell Calcium Imaging for Studying the Activation of Calcium Ion Channels
Published on: December 13, 2024
Dual Action Calcium-Sensing Receptor Modulator Unmasks Novel Mode-Switching Mechanism
Karen J Gregory1, Irina Kufareva2, Andrew N Keller1
1Drug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Monash University, Parkville, Victoria 3052, Australia.
Abstract:
Negative allosteric modulators (NAMs) of the human calcium-sensing receptor (CaSR) have previously failed to show efficacy in human osteoporosis clinical trials, but there is now significant interest in repurposing these drugs for hypocalcemic disorders and inflammatory lung diseases. However, little is known about how CaSR NAMs inhibit the response to endogenous activators. An improved understanding of CaSR negative allosteric modulation may afford the opportunity to develop therapeutically superior CaSR-targeting drugs. In an attempt to elucidate the mechanistic and structural basis of allosteric modulation mediated by the previously reported NAM, calhex231, we herein demonstrate that calhex231 actually potentiates or inhibits the activity of multiple CaSR agonists depending on whether it occupies one or both protomers in a CaSR dimer. These findings reveal a novel mechanism of mode-switching at a Class C G protein-coupled receptor that has implications for drug discovery and potential clinical utility.
Insights
Negative allosteric modulators (NAMs) targeting the calcium-sensing receptor (CaSR) exhibit mode-switching behavior. This CaSR NAM can potentiate or inhibit receptor activity, offering new therapeutic strategies.
Area of Science:
- Biochemistry
- Pharmacology
- Structural Biology
Background:
- Negative allosteric modulators (NAMs) of the calcium-sensing receptor (CaSR) have shown limited success in osteoporosis but are being explored for hypocalcemic and inflammatory lung diseases.
- The precise mechanisms by which CaSR NAMs inhibit responses to endogenous activators remain incompletely understood.
- Developing a deeper mechanistic insight into CaSR negative allosteric modulation is crucial for designing improved CaSR-targeting therapeutics.
Purpose of the Study:
- To elucidate the mechanistic and structural basis of allosteric modulation by the CaSR NAM, calhex231.
- To investigate how calhex231 interacts with the CaSR dimer to influence receptor activity.
- To explore the implications of novel allosteric modulation mechanisms for CaSR-targeting drug discovery.
Main Methods:
- Utilized biochemical assays to assess the activity of CaSR in the presence of calhex231 and various agonists.
- Employed structural biology techniques to determine the binding modes of calhex231 within the CaSR dimer.
- Analyzed the functional consequences of calhex231 occupying one versus both protomers of the CaSR dimer.
Main Results:
- Demonstrated that calhex231 exhibits mode-switching behavior, acting as a potentiator or inhibitor of CaSR activity.
- Showed that the effect of calhex231 is dependent on its binding stoichiometry within the CaSR dimer (one or both protomers).
- Identified a novel mechanism of allosteric modulation involving differential protomer occupancy in a Class C G protein-coupled receptor.
Conclusions:
- Calhex231 displays a unique mode-switching mechanism at the CaSR, challenging previous assumptions about NAM function.
- This discovery provides a new framework for understanding CaSR allosteric modulation.
- The findings have significant implications for the rational design of next-generation CaSR-targeting drugs with enhanced therapeutic potential.
Related Concept Videos
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Antihypertensive Drugs: Action of Calcium Channel Blockers
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...

